? Locally applied biomedical barriers and microbicides have proven ineffectual in preventing sexual transmission of HIV. HIV requires intact lipid rafts, cholesterol-rich subregions in cell membranes, for entry into cells and for budding of infectious particles. Beta-cyclodextrin (?-CD), a cyclic heptasaccharide that removes cholesterol from cell membranes and disperses lipid rafts, has been shown to block HIV infection and abolish infectivity of budding HIV particles. Cholesterol is also required by other pathogens including many viruses, some of which are associated with STDs such as HSV-2. ??-CD is non-toxic and in wide human use in food products and as a carrier for drugs. A number of studies in humans and animals have shown that ?-CD can be safely applied to mucosal surfaces. Thus properly formulated, this molecule may be a safe microbicide effective against HIV and other pathogens. The central hypothesis of this proposal is that because it efficiently depletes cholesterol from lipid membranes thereby blocking virus infection and has an extensive and well-established safety profile in humans, ?-CD is an outstanding candidate for use as topical vaginal HIV microbicide. Over the first two years of this project we have shown that ?-CD blocks HIV infection at the level of cells and virus and defined mechanisms by which the compound inactivates virions. We also showed that ?-CD effectively blocked vaginal HIV transmission in a Hu-SCID mouse model. Our studies have identified three criteria essential for the most effective HIV microbicide: inactivate every virus particle; do not disrupt the natural barriers to infection; and do not induce an inflammatory response. In continuing this project we will remain focused on mechanisms while optimizing parameters for use of ?-CD as an HIV microbicide.
The specific aims are: 1. To determine the effects of formulation of??-CD on its anti-HIV-1 activity; 2. To determine the effect of??-CD on vaginal epithelium in vitro and in vivo in mouse and rhesus macaque models; 3. To determine if deleterious effects of ?-CD on cell membranes can be attenuated by exogenous lipid; 4. To determine ?-CD is synergistic with other agents In blocking HIV infection. These studies should provide important insights regarding the development of HIV microbicides generally and ?-CD in particular. The results should provide the basis for further animal studies and pilot human studies of this novel microbicide candidate. ? ?

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project (R01)
Project #
5R01HD040772-06
Application #
7253880
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Kaufman, Steven
Project Start
2001-04-27
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$604,484
Indirect Cost
Name
Meharry Medical College
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041438185
City
Nashville
State
TN
Country
United States
Zip Code
37208
Walker, Tiffany N; Cimakasky, Lisa M; Coleman, Ebony M et al. (2013) Antibody against integrin lymphocyte function-associated antigen 1 inhibits HIV type 1 infection in primary cells through caspase-8-mediated apoptosis. AIDS Res Hum Retroviruses 29:371-83
Coleman, Ebony M; Walker, Tiffany N; Hildreth, James E K (2012) Loss of Niemann Pick type C proteins 1 and 2 greatly enhances HIV infectivity and is associated with accumulation of HIV Gag and cholesterol in late endosomes/lysosomes. Virol J 9:31
Emeagwali, Nkiruka; Hildreth, James E K (2012) Human immunodeficiency virus type 1 Vpu and cellular TASK proteins suppress transcription of unintegrated HIV-1 DNA. Virol J 9:277
Taylor, Harry E; Linde, Michael E; Khatua, Atanu K et al. (2011) Sterol regulatory element-binding protein 2 couples HIV-1 transcription to cholesterol homeostasis and T cell activation. J Virol 85:7699-709
Tang, Yuyang; Leao, Ihid Carneiro; Coleman, Ebony M et al. (2009) Deficiency of niemann-pick type C-1 protein impairs release of human immunodeficiency virus type 1 and results in Gag accumulation in late endosomal/lysosomal compartments. J Virol 83:7982-95
Scorpio, Diana G; Ruben, Dawn S; Liao, Zhaohao et al. (2008) Cervicovaginal evaluation in macaques used as a model for topical microbicide safety studies. J Med Primatol 37 Suppl 1:65-73
Leao, Ihid C; Maciel, Milton; Hildreth, James E K (2006) Production and characterization of a monoclonal antibody against Niemann Pick type C protein. Hybridoma (Larchmt) 25:216-24
Nguyen, Deborah Greene; Hildreth, James E K (2003) Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol 33:483-93